300 Phase I study of two dosing schedules of the investigational oral pan-RAF kinase inhibitor MLN2480 in patients (pts) with advanced solid tumors or melanoma by Rasco, D.W, Middleton, M.R, Gonzalez, R, Corrie, P, Pavlick, A, Lorigan, P, Plummer, R, Gore, M, Herbert, C, Agarwala, S.S, Logan, T.F, Khleif, S.N, Papadopoulos, K.P, Rangachari, L, Suri, A, Xu, Q, Kneissl, M, Bozón, V, Olszanski, A.J

Get full text